Ginsenoside Rg3 (Shenyi Capsule) Combined with Chemotherapy for Digestive System Cancer in China: A Meta-Analysis and Systematic Review
Open Access
- 17 December 2019
- journal article
- review article
- Published by Hindawi Limited in Evidence-Based Complementary and Alternative Medicine
- Vol. 2019, 1-19
- https://doi.org/10.1155/2019/2417418
Abstract
Objective. In China, ginsenoside Rg3 is often used in combination with chemotherapy to treat digestive system cancer. We here performed a meta-analysis and systematic review to provide a much needed high-quality evaluation of the efficacy and safety of ginsenoside Rg3 combined with chemotherapy in these cancers. Materials and Methods. The PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang, and Weipu (VIP) databases were searched. All randomized controlled trials (RCTs) concerning ginsenoside Rg3 combined with chemotherapy for digestive system cancer were selected. Dichotomous data were expressed as odds ratios (ORs) with 95 confidence intervals (CI). The methodological quality of the included studies was evaluated according to the Cochrane evidence-based medicine system, and the statistical analyses were performed with Review Manager 5.3 and STATA 12.0 software. In addition, the Grades of Recommendation Assessment, Development and Evaluation (GRADE) approach was used to rate the quality of the evidence. Trial sequential analysis (TSA) was used to evaluate information size and treatment benefits. Results. A total of 18 trials comprising 1531 patients were included in this study. The results revealed that the trials were of sufficient standard to draw reliable conclusions that ginsenoside Rg3 combined with chemotherapy could improve the objective response rate (ORR; OR 2.17, 95 CI 1.722.73), disease control rate (DCR; OR 2.83, 95 CI 2.023.96), 1-year survival rate (SR; OR=2.33, 95 CI=1.244.37), Karnofsky Performance Scale (KPS; OR 2.67, 95 CI 1.764.03), gastrointestinal dysfunction (OR 0.44, 95 CI 0.310.61), and the decline of leucocyte count (OR 0.28, 95 CI 0.210.38). Conclusion. Ginsenoside Rg3 combined with chemotherapy can improve the clinical efficacy and alleviate treatment-induced side effects for digestive system cancer.Keywords
Funding Information
- State Administration of Traditional Chinese Medicine of the People's Republic of China
This publication has 21 references indexed in Scilit:
- Vascular Endothelial Growth Factor A Regulates the Secretion of Different Angiogenic Factors in Lung Cancer CellsJournal of Cellular Physiology, 2015
- Ginsenoside Rg3 induces FUT4-mediated apoptosis in H. pylori CagA-treated gastric cancer cells by regulating SP1 and HSF1 expressionsToxicology in Vitro, 2015
- Ginsenoside Rg3 enhances radiosensitization of hypoxic oesophageal cancer cell lines through vascular endothelial growth factor and hypoxia inducible factor 1αJournal of International Medical Research, 2014
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Efficacy of Shenyi Capsule combined with gemcitabine plus cisplatin in treatment of advanced esophageal cancer: a randomized controlled trialJournal of Chinese Integrative Medicine, 2009
- Anxiety and distress during active surveillance for early prostate cancerCancer, 2009
- Revised Colorectal Screening Guidelines: Joint Effort of the American Cancer Society, U.S. Multisociety Task Force on Colorectal Cancer, and American College of RadiologyRadiology, 2008
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Detection of early gastric cancer: misunderstanding the role of mass screeningGastric Cancer, 2006